We’re entering an exciting new chapter at Immunophotonics as we announce key leadership transitions. After more than 15 years of visionary leadership, Lu Alleruzzo will be stepping down as CEO. Lu will continue to serve as a director and co-founder, working closely with Dr. Tomas Hode, our co-founder and Chief Innovation Officer, to advise the...
Over the past 15+ years – it has been my honor to help build Immunophotonics from its earliest vision into a company with great science, a strong global network and a mission that matters deeply to patients and clinicians. As we prepare for the next chapter of growth, I am excited and proud to welcome...
The Immunophotonics Team is proud to extend our heartfelt congratulations to a co-inventor of IP-001, Professor Wei Chen, on his appointment as Director of the Peggy and Charles Stephenson School of Biomedical Engineering (SBME) at the University of Oklahoma. Dr. Chen has long been a pioneer in the field of ablation-based immunotherapy, and his leadership,...
Members of our leadership team will be attending the CIRSE 2025 Annual Congress, organized by the Cardiovascular and Interventional Radiological Society of Europe, taking place in Barcelona, Spain, from September 13–17. Be sure to visit Robert Arch, PhD, SVP Corporate Development and Theresa Visarius, PhD, VP of Business Development at Booth #54 for an opportunity...
Unlocking the Power of the Immune System – One Product, Many Possibilities Immunophotonics is featured in BioSpace’s spotlight on biotechs embracing the “pipeline-in-a-product” approach. This strategy resonates deeply with our mission: to develop platform immunotherapies that activate the body’s own immune system to fight cancer and beyond. IP-001, our lead candidate, exemplifies this vision. Designed...
Immunophotonics announced the completion of the SAKK 66/17 Phase 1b/2a multicenter clinical trial, conducted in collaboration with the Swiss Cancer Institute. This marks a major step forward in evaluating the immunologically mediated anticancer effects of IP-001, our proprietary immune-stimulating drug, following thermal ablation in patients with advanced solid tumors. The trial assessed both safety and...
Immunophotonics has reached a major milestone in its clinical development efforts with the completion of treatment for the final patient in the INJECTABL-1 Phase 1b/2a trial of IP-001 for advanced solid tumors. The 41-patient, multicenter trial was conducted across the U.S., UK, France, Germany, and Switzerland, targeting colorectal cancer, non-small cell lung cancer, and soft...
Congratulations to Professor Wei Chen and his lab at the University of Oklahoma on their recent publication titled “Anti-tumor effects on tumor-infiltrating natural killer cells by localized ablative immunotherapy and immune checkpoint inhibitors: An integrated and comparative study using scRNAseq analysis” in Elsevier Cancer Letters. Elsevier Cancer Letters, an international journal, provides a forum for...
Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma AG) served as a keynote speaker and panelist at the International Growth Leaders, Driving Global Success event of the Swiss Association of MBAs, held June 24th in Switzerland. This event brought together global leaders to explore strategies for market expansion and offered valuable insights into navigating cross-border...
Lu Alleruzzo (CEO) and Robert Arch (SVP of Corporate Development) at Immunophotonics, Inc. will be attending the BIO International Convention in Boston from June 16-19, 2025. This event is among the largest biotechnology events for global industry leaders and investors. They are looking forward to connecting with biotech leaders, investors, and partners who share a passion for transforming patient outcomes...
